Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 6th Floor, Room m6-201, 60 Murray Street, Toronto, ON, Canada.
Clinical biochemistry (Impact Factor: 2.28). 03/2009; 42(4-5):426-9. DOI: 10.1016/j.clinbiochem.2008.11.008
Source: PubMed


Objectives: To identify autoantibody signatures in ovarian cancer using protein microarray technology. Design and methods: Protein microarrays were screened using non-malignant peritoneal fluid (n=30) and ascites fluid pooled from ovarian cancer patients (n=30). Results: Fifteen potential tumour-associated antigens were discovered. AASDHPPT showed the strongest signal-to-noise ratio. Conclusions: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.


Available from: Nader Memari, Aug 06, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Each year in the United States over 15,000 women die of epithelial ovarian cancer (EOC) and 22,000 are diagnosed with the disease. The incidence of ovarian cancer has remained stable over the past decade however, survival rates have improved steadily. Increases in survival rates can be attributed to the advances in surgical management, development of effective cytotoxic drugs and the route of administration of chemotherapy. Ovarian cancer survival rates could also be improved through screening and early detection. Disappointingly, effective screening methods have not been established and continue to be elusive. Historically the goal of a screening test was to achieve a positive predictive value (PPV) greater than 10% in order be considered cost effective and have an acceptable risk for the population being screened. Despite the inability of currently available screening algorithms to achieve the desired PPV there may be an advantage in producing a stage migration to lower stages at the time of diagnoses, thereby resulting in improved survival. Equally important recent studies have demonstrated that women who have their initial surgery performed by gynecologic oncologists, and women who have their surgeries at centers experienced in the treatment of ovarian cancer have higher survival rates. For these reasons it is essential that all women at high risk for ovarian cancer receive their initial care by gynecologic oncologists and at centers with multidisciplinary teams experienced in the optimal care of ovarian cancer patients. With this in mind, methods that facilitate the accurate triage of women who will ultimately be diagnosed with ovarian cancer could play a significant role in improving survival rates for these patients. This review article will examine the current state of biomarker use in ovarian cancer screening, risk assessment and for monitoring ovarian cancer patients.
    Gynecologic Oncology 10/2009; 116(2):240-5. DOI:10.1016/j.ygyno.2009.09.041 · 3.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer (CRC) is a widespread disease, whose major genetic changes and mutations have been well characterized in the sporadic form. Much less is known at the protein and proteome level. Still, CRC has been the subject of multiple proteomic studies due to the urgent necessity of finding clinically relevant markers and to elucidate the molecular mechanisms underlying the progression of the disease. These proteomic approaches have been limited by different technical issues, mainly related with sensitivity and reproducibility. However, recent advances in proteomic techniques and MS systems have rekindled the quest for new biomarkers in CRC and an improved molecular characterization. In this review, we will discuss the application of different proteomic approaches to the identification of differentially expressed proteins in CRC. In particular, we will make a critical assessment about the use of 2-D DIGE, MS and protein microarray technologies, in their different formats, to identify up- or downregulated proteins and/or autoantibodies profiles that could be useful for CRC characterization and diagnosis. Despite a wide list of potential biomarkers, it is clear that more scientific efforts and technical advances are still needed to cover the range of low-abundant proteins, which may play a key role in CRC diagnostics and progression.
    PROTEOMICS - CLINICAL APPLICATIONS 02/2010; 4(2):159-78. DOI:10.1002/prca.200900131 · 2.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine the serum HER-2/neu autoantibody level in patients with epithelial ovarian cancer and to evaluate the potential of using HER-2/neuautoantibody as a tumor marker. Methods: The serum HER-2/neu autoantibody levels were measured by ELISA in 20 normal controls, 20 patients with benign epithelial ovarian tumors and 40 patients with epithelial ovarian cancer during 2007 to 2009. Statistical analysis was performed to determine the diagnostic value of serum HER-2/neu autoantibody. Results: The sera of epithelial ovarian cancer patients expressed higher levels of HER-2/neu autoantibody than those of benign epithelial ovarian tumor patients and normal controls (P<0.05). The ROC curve results showed that the HER-2/neu autoantibody screening exhibited a sensitivity of 47.5% and a specificity of 97.5% for diagnosis of epithelial ovarian cancer. Compared with serum CA125 measurement, the combined measurement of CA125 and HER-2/neu autoantibody yielded an increased specificity of 90% without decreasing the sensitivity. And no association was found for serum CA125 and HER-2/neu autoantibody using partial correlation coefficient. Conclusion: It is shown that the serum HER-2/neu autoantibody level is associated with epithelial ovarian cancer and can serve as a potential serological biomarker for epithelial ovarian cancer diagnosis.
    Academic Journal of Second Military Medical University 10/2010; 30(10):1076-1080. DOI:10.3724/SP.J.1008.2010.01076
Show more